News 2018-10-06
Porton will attend 2018 CPhI WW
We own and operate 4 Process Technology Centers and 2 Manufacturing Sites [including one US FDA, Japan PDMA-approved facilities] across China. Supported by >1,500 customer first-oriented employees [including >500 Process Scientists, Operations, Quality Assurance, EHS and Program Management professionals]. Our sites are operated to global quality and environmental standards under a centralized management system.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - March 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
